Opthea Limited

OTCPK:OPTE.Y Stock Report

Market Cap: US$585.4m

Opthea Management

Management criteria checks 2/4

Opthea's CEO is Jeremy Levin, appointed in Sep 2025, has a tenure of less than a year. directly owns 0.005% of the company’s shares, worth $26.93K. The average tenure of the management team and the board of directors is 0.6 years and 1.8 years respectively.

Key information

Jeremy Levin

Chief executive officer

AU$810.7k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.005%
Management average tenureless than a year
Board average tenure1.8yrs

Recent management updates

Recent updates

Seeking Alpha • Jan 30

Opthea: Small Australian Company Aiming To Upend The Wet AMD Market

Summary Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD, showing promising Phase 2b results. Wet AMD treatments like Lucentis and Eylea have limitations; sozinibercept aims to improve efficacy by targeting a broader VEGF family. Financially, Opthea has a market cap of $797mn and a cash runway of 4-5 quarters, but faces transparency and dilution risks. Despite compelling data, market entry challenges and low trading volume make me cautious; I await topline data before investing. Read the full article on Seeking Alpha
Seeking Alpha • Nov 07

Opthea Limited: Major Catalyst In Early 2025 For Complementary Eye Disease Candidate

Summary Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 results due in 2025. The wet AMD market is lucrative, but the challenge lies in the patient's willingness to receive two intravitreal injections for potentially better outcomes. Phase 2b results were promising, but Phase 3 studies face uncertainties due to different standards of care and longer study durations, amongst other reasons. Opthea's financial pressure and competitive landscape make it a risky investment; I assign a "Hold" rating pending Phase 3 outcomes. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Opthea GAAP EPS of -$0.26 misses by $0.03

Opthea press release (NASDAQ:OPT): FY GAAP EPS of -$0.26 misses by $0.03. As of June 30, 2022, Opthea had cash, cash equivalents and short-term investments of $44.6 million.
Seeking Alpha • Aug 15

Opthea receives $170M in non-dilutive financing for OPT-302 in wet AMD

Opthea (NASDAQ:OPT) entered into a non-dilutive financing transaction for up to $170M from investment funds working with Launch Therapeutics to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration. Launch Tx is the recently formed development company backed by funds managed by global investment firm Carlyle and its life sciences franchise, Abingworth. Under agreement terms, the funds managed by Carlyle and Abingworth, in collaboration with Launch Tx, will commit $120M in three installments at fixed time points and retain an option to commit another $50M. Opthea retains full worldwide commercial rights for OPT-302 and has the option to prepay its obligations in full at any time. "This strategic transaction is expected to fund us through Phase 3 topline data expected in mid-2024 and strengthens our strategic position to maximize the value of OPT-30," CEO Dr Megan Baldwin commented.

CEO

Jeremy Levin (72 yo)

less than a year
Tenure
AU$810,703
Compensation

Dr. Jeremy Max Levin, M.D., Ph D., BA Zoology, DPhil, MB BChir, is Executive Chairman of Ovid Therapeutics Inc. from January 1, 2026 and has been its Chairman since April 2014 and serves as its Director si...

Leadership Team

NamePositionTenureCompensationOwnership
Jeremy Levin
CEO & Chairpersonless than a yearAU$810.70k0.0046%
$ 26.9k
Hamish George
CFO & Joint Company Secretaryless than a yearno datano data
Stuart Mudge
Chief Operating Officerless than a yearno datano data
Michael Gerometta
Chief Technology Officerless than a yearAU$208.93kno data
Stephanie Vipond
Joint Company Secretaryless than a yearno datano data
0.6yrs
Average Tenure

Experienced Management: OPTE.Y's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jeremy Levin
CEO & Chairperson5.6yrsAU$810.70k0.0046%
$ 26.9k
Lawrence Gozlan
Independent Non-Executive Director5.8yrsAU$1.23m0.14%
$ 803.4k
Katherine Connell
Independent Non-Executive Director1.5yrsAU$132.57kno data
Patricio Schlottmann
Member of Medical Advisory Board1.8yrsno datano data
Tien Wong
Member of Medical Advisory Board1.8yrsno datano data
1.8yrs
Average Tenure
57yo
Average Age

Experienced Board: OPTE.Y's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/25 19:39
End of Day Share Price 2026/05/22 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Opthea Limited is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elyse ShapiroCanaccord Genuity
John SavinEdison Investment Research
Chris CooperGoldman Sachs